Heat Biologics, Inc. (HTBX)
HTBX Stock Price Chart
|Net Income (ttm)||-22.93M|
|Trading Day||December 4|
|Day's Range||1.06 - 1.10|
|52-Week Range||0.21 - 3.62|
HTBX Stock News
Heat Biologics boosts patents portfolio with gp96 combination award. Teleflex announces acquisition of hemostatic company Z-Medica.
Heat Biologics (HTBX) is in the news Thursday as HTBX stock takes a wild ride following an increasing focus on coronavirus stocks. The post Heat Biologics News: Why HTBX Stock Is On the Move T...
COVID-19 vaccine stocks have gotten slammed this month.
A pre-print is sending the biotech's shares higher today.
Reports of an early approval for AstraZeneca's COVID-19 vaccine are sending these three stocks lower today.
Encouraging early results for the biotech's coronavirus vaccine have investors excited.
Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.
Heat Biologics and Vaxart could have a lot more room to run.
The biotech's COVID-19 vaccine candidate hit the mark in a preclinical study.
Heat Biologics Inc (NASDAQ: HTBX) shares are trading higher on Monday after the company announced the first patient has been treated in its first-in-human clinical trial of PTX-35.
The market is powering through its third consecutive day of massive gains. Whether the market is too optimistic has been on the minds of many, considering how unstable the economy has been thi...
As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks t...
Heat Biologics, a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T... [Read more...]
|IPO Date |
Jul 24, 2013
|Stock Exchange |
|Ticker Symbol |
In 2019, Heat Biologics's revenue was $3.05 million, a decrease of -47.37% compared to the previous year's $5.79 million. Losses were -$20.02 million, 27.2% more than in 2018.